CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Iroko Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Iroko Pharmaceuticals Inc
150 Rouse Boulevard, One Kew P
Phone: (267) 546-3003p:267 546-3003 PHILADELPHIA, PA  19112  United States
Iroko Pharmaceuticals Inc. filed a Registration Withdrawal Request of its Form F-1 (Reg No. 333-189428) with the SEC on 7/31/2013. The Company is requesting withdrawal of the Registration Statement due to the Company’s decision not to proceed with the initial public offering contemplated by the Registration Statement. No securities were sold pursuant to the Registration Statement.
Business Summary
Iroko Pharmaceuticals Inc. is a global, specialty pharmaceutical company focused on the development and commercialization of novel nonsteroidal anti-inflammatory drug, or NSAID, therapeutics for patients with mild to moderate acute and chronic pain. The Company's pipeline includes six submicron NSAID product candidates, two of which have been submitted to the U.S. Food and Drug Administration or FDA for marketing approval. It uses the iCeutica proprietary SoluMatrix™ technology platform, which it has exclusively licensed, or has the option to exclusively license, for all NSAIDs, to create submicron, lower dose formulations of established NSAIDs. NSAIDs are one of the largest classes of pain-relieving medications and have been a mainstay of treatment for a variety of pain related conditions notwithstanding their potential adverse side effects. The proprietary technology platform the Company uses has been shown, at a statistically significant level in clinical studies, to fundamentally change the absorption profile of its late-stage NSAID product candidates so that they are quickly dissolved and absorbed to allow for rapid onset of pain relief at lower doses and lower systemic exposures, as measured by plasma levels of a drug over time, than the comparable commercially available NSAID, which are diclofenac, indomethacin, and naproxen. The Company is applying this proprietary technology platform to additional NSAID molecules in preclinical development and expects to experience similar results.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201312/31/2012YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Osagie O.Imasogie 51
President, Chief Executive Officer John F.Vavricka 49
Chief Financial Officer Fred C.Krieger 66
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
iCeutica, Inc. 1 Crescent Drive Philadelphia PA United States

Business Names
Business Name
iCeutica, Inc.
Iroko Pharmaceuticals

General Information
Number of Employees: 71 (As of 3/31/2013)
Outstanding Shares: 31,753,549 (As of 7/30/2013)
Stock Exchange: NASD


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023